How to Acquire an Italian Life Sciences or Healthcare Company (2026): Step-by-step M&A Checklist for Cross-border Buyers

Acquiring a life sciences company in Italy in 2026 demands that cross-border buyers plan regulatory approvals and screening clearances from the very first screening call, not after signing. Italian life sciences and healthcare assets, biotech platforms, med-tech developers, contract manufacturers and reimbursement-backed pharmaceutical portfolios, have become sought-after targets, yet they sit inside a regulatory architecture that overlays ordinary corporate M&A with marketing authorisation transfers, manufacturing licence notifications, pharmacovigilance continuity and heightened foreign direct investment (FDI) scrutiny. The 2026 environment is defined by continuing golden-power intervention, ongoing capital markets reform affecting listed targets, and a patchwork of EU and national rules that reward early sequencing and punish late filings.

This guide sets out a practical, step-by-step M&A checklist for foreign acquirers, in-house counsel, and private equity and venture investors, covering the approvals, documents, timelines, costs and pitfalls that determine whether a deal closes on schedule.

1. Overview: deal pathways and what makes life sciences different

Every acquisition of an Italian life sciences or healthcare company begins with a structural choice, but in this sector that choice carries regulatory consequences far beyond tax and liability. The underlying regulated assets, marketing authorisations (MAs), manufacturing authorisations, clinical trial approvals and reimbursement listings, do not move automatically with corporate ownership. A share deal that changes control at the top of the group may leave the MA holder legally unchanged while still triggering notification obligations; an asset deal may require a formal MA transfer procedure for every product carved out. Sequencing the corporate transaction around these regulated transfers is the single most important planning task when acquiring a life sciences company in Italy.

1.1 Share purchase vs asset purchase vs statutory merger, quick comparison

The three principal pathways differ in how they treat regulated licences, historical liabilities and non-assignable contracts. A full side-by-side comparison appears in Section 9. In outline:

• Share purchase. The target retains its MAs and manufacturing authorisations; the legal holder is unchanged, but the change of control may still require notification and may trigger regulatory, antitrust and golden-power review. The buyer inherits historical liabilities unless indemnified.
• Asset purchase. Assets can be carved out selectively, but each MA typically requires a formal transfer to the new holder, and some contracts, particularly public procurement and hospital supply tenders, may not be assignable without consent.
• Statutory merger. Produces a consolidated transfer of assets and liabilities by operation of law, but may trigger the broadest set of regulatory notifications and is procedurally more complex.

1.2 Key regulatory overlays in life sciences

Four overlays distinguish life sciences deals from ordinary corporate M&A. First, marketing authorisations: nationally authorised medicines fall within the remit of the Agenzia Italiana del Farmaco (AIFA), while centrally authorised products follow European Medicines Agency (EMA) transfer procedures. Second, Good Manufacturing Practice (GMP) and manufacturing authorisations, which require continuity of the Qualified Person and the quality management system. Third, clinical data and ongoing trial authorisations, governed by both regulatory and data-protection rules. Fourth, healthcare procurement and reimbursement dossiers, which determine a product’s commercial value and whose continuity cannot be assumed on a change of control.

2. Eligibility and pre-deal screening

Before committing to a target, a buyer must establish which clearance regimes apply. Three can run in parallel: FDI/golden-power review, Italian merger control before the Autorità Garante della Concorrenza e del Mercato (AGCM), and, where thresholds are met, EU merger control before the European Commission. Each has independent triggers, so a single deal may require all three, one, or none.

2.1 When FDI and golden-power screening applies in Italy

Italy’s golden-power regime allows the Government to review, condition or block acquisitions touching strategic sectors, and health has been firmly within its perimeter in recent years. The regime operates alongside the EU-wide framework established by Regulation (EU) 2019/452, which provides for cooperation and information-sharing between Member States and the European Commission on FDI screening. Typical triggers in the health space include the acquisition of critical health infrastructure, strategic suppliers of medicines or medical devices, and companies conducting research or production of therapeutics considered strategically significant. Foreign acquirers, and in some circumstances EU acquirers too, should assume golden-power analysis is required and build it into the timetable rather than treating it as a formality.

Golden-power decisions are adopted by the Presidenza del Consiglio dei Ministri, and relevant measures may be published in the Gazzetta Ufficiale.

2.2 When Italian or EU merger control applies

Merger control turns on turnover thresholds and, in some analyses, market-share considerations. Where the Italian thresholds are met, a concentration must be notified to the AGCM before completion. Where the larger EU thresholds are met, the deal falls instead to the European Commission under the EU Merger Regulation, and the national filing is displaced. Because life sciences markets are often narrowly defined by therapeutic area or device class, even mid-sized deals can raise substantive overlap concerns that extend the review.

3. Step-by-step M&A checklist for acquiring a life sciences company in Italy

The checklist below sequences the corporate deal alongside the regulatory and antitrust workstreams that must run in parallel. The guiding principle when acquiring a life sciences company in Italy is to launch regulatory pre-engagement and clearance analysis early, ideally during due diligence, so that MA transfers, merger control and golden-power do not become the critical path to closing. Each step identifies the lead actor and an indicative duration; the consolidated timeline table follows.

1. Initial target screening and pre-LOI regulatory flags. Lead: buyer’s corporate and regulatory counsel. Scan for red flags before committing: expired or suspended MAs, orphan-drug designations, the status of reimbursement dossiers, any clinical holds, pending GMP findings and open pharmacovigilance signals. These flags determine deal structure and pricing.
2. Confidentiality agreements and early data room access. Lead: buyer counsel and target legal. Put a robust NDA in place, and address data protection at the outset, clinical and patient data in the data room engage the GDPR and the oversight of the Garante per la protezione dei dati personali. Pseudonymise trial data and document the lawful basis for any cross-border transfer.
3. Exclusivity and letter of intent. Lead: buyer and seller. Make the LOI conditional on the required regulatory approvals and on the successful transfer of marketing authorisations. Flag golden-power and merger control as conditions precedent so neither party is surprised later.
4. Comprehensive due diligence. Lead: buyer’s multidisciplinary team plus specialist advisers. Cover commercial, financial, tax, regulatory, quality (GMP), clinical, intellectual property, data protection and procurement contracts. In life sciences, regulatory and quality diligence is as important as the financial model: a single unresolved GMP non-compliance or a lapsed clinical trial authorisation can change valuation materially.
5. Regulatory pre-notification and informal engagement. Lead: regulatory affairs counsel. Engage AIFA, the Ministero della Salute and, where relevant, local health authorities early. For centrally authorised products, map the EMA transfer path. Prepare a pre-meeting checklist covering product lists, MA numbers, manufacturing sites and the proposed new holder.
6. Drafting and negotiating the SPA. Lead: M&A counsel. Build the regulatory architecture into the agreement: closing conditions tied to clearances, detailed MA transfer mechanics, representations on regulatory compliance, indemnities for product and pharmacovigilance liabilities, and escrow to cover recall or regulatory risk.
7. Formal regulatory filings. Lead: regulatory affairs plus the seller or incoming MA holder. File the AIFA change-of-ownership or MA transfer applications, update medical device vigilance records, and notify or apply for transfer of manufacturing authorisations. Assemble the forms and fees set out in the required-documents and costs tables below.
8. Merger control filing. Lead: competition counsel. File with the AGCM where national thresholds are met, or with the European Commission where EU thresholds apply. Respect the standstill obligation: concentrations within the scope of EU merger control must not be implemented before clearance, and the Italian regime imposes its own pre-completion notification requirements.
9. Golden-power / FDI notification. Lead: public-law counsel and buyer. Where the regime applies, file the notification and observe the review period. Agree protective covenants in the SPA to allocate the risk of conditions or a veto, and do not complete before the clearance window closes.
10. Closing and handover of regulatory responsibilities. Lead: buyer’s regulatory affairs and quality teams with the seller. Transfer pharmacovigilance obligations, including the Qualified Person responsible for pharmacovigilance (QPPV), batch quality assurance and the quality management system. Continuity here is non-negotiable: safety reporting cannot lapse at closing.
11. Post-closing integration and monitoring. Lead: integration lead and compliance team. Complete MA transfers that run past closing, monitor post-approval commitments, integrate quality systems and verify that reimbursement listings and procurement contracts remain in force.

3.1 Step / who / duration timeline

4. Required documents and dossier checklist

Life sciences due diligence demands two distinct document sets: the corporate and financial records common to any M&A transaction, and the sector-specific regulatory and quality dossiers that underpin the target’s licences and products. Gaps in the regulatory set are the most common cause of delayed closings, so request these early and treat missing items as diligence red flags rather than administrative loose ends.

5. Timeline and deadlines

The overall timetable for acquiring a life sciences company in Italy is usually set not by the corporate negotiation but by the longest regulatory workstream. Regulatory filings are the typical bottleneck: an AIFA change-of-ownership or MA transfer can take from roughly one to six months depending on the procedure and the number of products, while centrally authorised medicines follow EMA transfer timelines. Merger review before the AGCM proceeds through an initial (Phase I) examination that can extend to several months where an in-depth (Phase II) investigation or remedies are needed. Golden-power review runs for a statutory period that can be extended or suspended if the authorities request further information.

Standstill obligations in merger control, and the suspensive nature of golden-power review, mean completion must wait for clearance, plan these deadlines against the step timeline above and never assume parallel tracks will converge neatly. Verify current statutory periods directly with the relevant authorities, as they may change.

6. Costs, fees and filing charges

Transaction costs in a life sciences acquisition split between professional fees and statutory filing charges, with the regulatory workstream adding costs that do not arise in ordinary M&A. The principal cost drivers are the number of products requiring MA transfer, the breadth of regulatory and quality diligence, and whether golden-power and merger control filings are triggered. Indicative ranges are set out below; actual figures depend on deal size and complexity, and buyers should obtain tailored fee estimates and verify current statutory fees directly with the relevant authorities.

7. What changes in 2026 for acquiring a life sciences company in Italy

The 2026 landscape maintains heightened scrutiny rather than relaxing it, and this directly affects anyone acquiring a life sciences company in Italy. The clearest feature is continued FDI and golden-power enforcement: health infrastructure, strategic medicine and device suppliers and research into strategically significant therapeutics remain high-priority targets for Government review, and buyers should expect active engagement rather than light-touch clearance. The EU framework under Regulation (EU) 2019/452 continues to underpin cooperation between national screening authorities, reinforcing the national regime. Ongoing capital markets reform affects the mechanics of acquiring listed targets, from disclosure to takeover procedure, and should be factored into any public-company bid.

On the regulatory side, buyers should verify current AIFA and EMA procedures and fee schedules directly, as administrative processes and timelines evolve. The practical takeaway for 2026 is unchanged in principle but sharper in degree: start clearance analysis at screening, and budget realistic time for golden-power and merger review.

8. Common pitfalls and how to avoid them

• Ignoring golden-power triggers. Treating FDI screening as optional for a health target invites suspension or unwinding; analyse applicability at the LOI stage.
• Filing regulatory applications too late. MA and manufacturing licence transfers are the usual critical path; launch pre-engagement during diligence, not after signing.
• Inadequate QMS transfer planning. A quality management system that lapses or fragments at closing threatens GMP compliance; plan the handover in detail.
• Mishandling pharmacovigilance. Safety reporting and QPPV responsibility cannot pause during transition; agree transitional arrangements explicitly.
• Underestimating antitrust thresholds. Narrow therapeutic markets can create overlaps that trigger in-depth review; model market definition early.
• Insufficient escrow for recall or product liability. Build holdbacks and indemnities sized to realistic regulatory and product risk.
• Not mapping reimbursement dossiers. A product’s value depends on its listing; confirm reimbursement status and renewal exposure.
• Overlooking non-assignable contracts. Public procurement and hospital supply tenders may require consent; identify change-of-control clauses in diligence.
• Neglecting GDPR in clinical data. Trial and patient data in the data room engage the Garante’s requirements; pseudonymise and document transfers.
• Under-resourcing integration. Post-closing MA transfers, system integration and compliance monitoring can run for months; staff the integration function properly.

9. Comparison table: asset vs share vs statutory merger for life sciences targets

The structure chosen shapes how licences transfer, how liabilities travel and whether key contracts survive. The table below isolates the life-sciences-specific considerations that should inform the decision.

Conclusion and next steps

Acquiring a life sciences company in Italy in 2026 rewards buyers who treat regulatory clearance as the backbone of the transaction rather than an afterthought. Golden-power scrutiny is active, merger control can turn on narrowly defined markets, and marketing authorisation and manufacturing licence transfers routinely set the closing date. The buyers who close on schedule are those who flag regulatory risk at screening, run the corporate, antitrust and regulatory workstreams in parallel, and size their SPA protections to real product and compliance exposure. For tailored advice on structuring and executing a deal, consult the Italy, Business practice area or find Italy life sciences and healthcare lawyers on the GLE directory.

Sources

1. Agenzia Italiana del Farmaco (AIFA)
2. Ministero della Salute
3. European Medicines Agency (EMA)
4. EUR-Lex, Regulation (EU) 2019/452 (FDI screening)
5. Gazzetta Ufficiale della Repubblica Italiana
6. Presidenza del Consiglio dei Ministri (Government of Italy)
7. Autorità Garante della Concorrenza e del Mercato (AGCM)
8. Garante per la protezione dei dati personali
9. European Commission, Mergers / Competition